← Back to Search

Stem Cell Transplant

Cord Blood Transplant for Blood Disorders

Phase 2
Recruiting
Led By Richard W Childs, M.D.
Research Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must not have
Patients who are receiving licensed CB products (only)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post transplant
Awards & highlights
No Placebo-Only Group

Summary

This trial will test the safety of unlicensed cord blood units in people who need stem cell transplants.

Who is the study for?
This trial is for individuals of any age and gender who need a stem cell transplant due to conditions like leukemia, lymphoma, or anemia. They must be part of another clinical trial for the transplant and give informed consent. Those already receiving unlicensed cord blood from other banks or licensed products only cannot participate.
What is being tested?
The study tests the safety and effectiveness of unlicensed cord blood units used in stem cell transplants. Participants will receive these units during their standard transplant procedure and will be monitored for up to one year for any issues.
What are the potential side effects?
Potential side effects are related to stem cell transplantation procedures which may include infection risk, graft-versus-host disease (where transplanted cells attack your body), bleeding complications, organ damage, and reactions to the infusion.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently using approved cannabinoid-based products.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year post transplant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cone-Rod Dystrophy 2

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
at least one

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)Lead Sponsor
3,938 Previous Clinical Trials
47,791,798 Total Patients Enrolled
90 Trials studying Leukemia
10,448 Patients Enrolled for Leukemia
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,022,670 Total Patients Enrolled
1,534 Trials studying Leukemia
385,041 Patients Enrolled for Leukemia
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,327 Previous Clinical Trials
5,365,489 Total Patients Enrolled
5 Trials studying Leukemia
412 Patients Enrolled for Leukemia
National Cord Blood Program, New York Blood CenterUNKNOWN
Richard W Childs, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
18 Previous Clinical Trials
8,257 Total Patients Enrolled
2 Trials studying Leukemia
237 Patients Enrolled for Leukemia

Media Library

Cord Blood Units (Stem Cell Transplant) Clinical Trial Eligibility Overview. Trial Name: NCT01861093 — Phase 2
Leukemia Research Study Groups: 1
Leukemia Clinical Trial 2023: Cord Blood Units Highlights & Side Effects. Trial Name: NCT01861093 — Phase 2
Cord Blood Units (Stem Cell Transplant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01861093 — Phase 2
~292 spots leftby Nov 2037
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top